Cargando…

Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients

BACKGROUND: SARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19. METHODS: To discover sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannella, Alessandra, Riccetti, Silvia, Sinigaglia, Alessandro, Piubelli, Chiara, Razzaboni, Elisa, Di Battista, Piero, Agostini, Matteo, Dal Molin, Emanuela, Manganelli, Riccardo, Gobbi, Federico, Ceolotto, Giulio, Barzon, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403711/
https://www.ncbi.nlm.nih.gov/pubmed/36032130
http://dx.doi.org/10.3389/fimmu.2022.968991
_version_ 1784773440288325632
author Giannella, Alessandra
Riccetti, Silvia
Sinigaglia, Alessandro
Piubelli, Chiara
Razzaboni, Elisa
Di Battista, Piero
Agostini, Matteo
Dal Molin, Emanuela
Manganelli, Riccardo
Gobbi, Federico
Ceolotto, Giulio
Barzon, Luisa
author_facet Giannella, Alessandra
Riccetti, Silvia
Sinigaglia, Alessandro
Piubelli, Chiara
Razzaboni, Elisa
Di Battista, Piero
Agostini, Matteo
Dal Molin, Emanuela
Manganelli, Riccardo
Gobbi, Federico
Ceolotto, Giulio
Barzon, Luisa
author_sort Giannella, Alessandra
collection PubMed
description BACKGROUND: SARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19. METHODS: To discover signatures of circulating miRNAs associated with COVID-19, disease severity and mortality, small RNA-sequencing was performed on serum samples collected from 89 COVID-19 patients (34 severe, 29 moderate, 26 mild) at hospital admission and from 45 healthy controls (HC). To search for possible sources of miRNAs, investigation of differentially expressed (DE) miRNAs in relevant human cell types in vitro. RESULTS: COVID-19 patients showed upregulation of miRNAs associated with lung disease, vascular damage and inflammation and downregulation of miRNAs that inhibit pro-inflammatory cytokines and chemokines, angiogenesis, and stress response. Compared with mild/moderate disease, patients with severe COVID-19 had a miRNA signature indicating a profound impairment of innate and adaptive immune responses, inflammation, lung fibrosis and heart failure. A subset of the DE miRNAs predicted mortality. In particular, a combination of high serum miR-22-3p and miR-21-5p, which target antiviral response genes, and low miR-224-5p and miR-155-5p, targeting pro-inflammatory factors, discriminated severe from mild/moderate COVID-19 (AUROC 0.88, 95% CI 0.80-0.95, p<0.0001), while high leukocyte count and low levels of miR-1-3p, miR-23b-3p, miR-141-3p, miR-155-5p and miR-4433b-5p predicted mortality with high sensitivity and specificity (AUROC 0.95, 95% CI 0.89-1.00, p<0.0001). In vitro experiments showed that some of the DE miRNAs were modulated directly by SARS-CoV-2 infection in permissive lung epithelial cells. CONCLUSIONS: We discovered circulating miRNAs associated with COVID-19 severity and mortality. The identified DE miRNAs provided clues on COVID-19 pathogenesis, highlighting signatures of impaired interferon and antiviral responses, inflammation, organ damage and cardiovascular failure as associated with severe disease and death.
format Online
Article
Text
id pubmed-9403711
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94037112022-08-26 Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients Giannella, Alessandra Riccetti, Silvia Sinigaglia, Alessandro Piubelli, Chiara Razzaboni, Elisa Di Battista, Piero Agostini, Matteo Dal Molin, Emanuela Manganelli, Riccardo Gobbi, Federico Ceolotto, Giulio Barzon, Luisa Front Immunol Immunology BACKGROUND: SARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19. METHODS: To discover signatures of circulating miRNAs associated with COVID-19, disease severity and mortality, small RNA-sequencing was performed on serum samples collected from 89 COVID-19 patients (34 severe, 29 moderate, 26 mild) at hospital admission and from 45 healthy controls (HC). To search for possible sources of miRNAs, investigation of differentially expressed (DE) miRNAs in relevant human cell types in vitro. RESULTS: COVID-19 patients showed upregulation of miRNAs associated with lung disease, vascular damage and inflammation and downregulation of miRNAs that inhibit pro-inflammatory cytokines and chemokines, angiogenesis, and stress response. Compared with mild/moderate disease, patients with severe COVID-19 had a miRNA signature indicating a profound impairment of innate and adaptive immune responses, inflammation, lung fibrosis and heart failure. A subset of the DE miRNAs predicted mortality. In particular, a combination of high serum miR-22-3p and miR-21-5p, which target antiviral response genes, and low miR-224-5p and miR-155-5p, targeting pro-inflammatory factors, discriminated severe from mild/moderate COVID-19 (AUROC 0.88, 95% CI 0.80-0.95, p<0.0001), while high leukocyte count and low levels of miR-1-3p, miR-23b-3p, miR-141-3p, miR-155-5p and miR-4433b-5p predicted mortality with high sensitivity and specificity (AUROC 0.95, 95% CI 0.89-1.00, p<0.0001). In vitro experiments showed that some of the DE miRNAs were modulated directly by SARS-CoV-2 infection in permissive lung epithelial cells. CONCLUSIONS: We discovered circulating miRNAs associated with COVID-19 severity and mortality. The identified DE miRNAs provided clues on COVID-19 pathogenesis, highlighting signatures of impaired interferon and antiviral responses, inflammation, organ damage and cardiovascular failure as associated with severe disease and death. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403711/ /pubmed/36032130 http://dx.doi.org/10.3389/fimmu.2022.968991 Text en Copyright © 2022 Giannella, Riccetti, Sinigaglia, Piubelli, Razzaboni, Di Battista, Agostini, Dal Molin, Manganelli, Gobbi, Ceolotto and Barzon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Giannella, Alessandra
Riccetti, Silvia
Sinigaglia, Alessandro
Piubelli, Chiara
Razzaboni, Elisa
Di Battista, Piero
Agostini, Matteo
Dal Molin, Emanuela
Manganelli, Riccardo
Gobbi, Federico
Ceolotto, Giulio
Barzon, Luisa
Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
title Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
title_full Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
title_fullStr Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
title_full_unstemmed Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
title_short Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
title_sort circulating microrna signatures associated with disease severity and outcome in covid-19 patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403711/
https://www.ncbi.nlm.nih.gov/pubmed/36032130
http://dx.doi.org/10.3389/fimmu.2022.968991
work_keys_str_mv AT giannellaalessandra circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT riccettisilvia circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT sinigagliaalessandro circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT piubellichiara circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT razzabonielisa circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT dibattistapiero circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT agostinimatteo circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT dalmolinemanuela circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT manganelliriccardo circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT gobbifederico circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT ceolottogiulio circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients
AT barzonluisa circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients